**Research Paper** 

# PGC-1 $\alpha$ controls mitochondrial biogenesis and dynamics in lead-induced neurotoxicity

Aleksandra Dabrowska<sup>1</sup>, Jose Luis Venero<sup>2</sup>, Ryota Iwasawa<sup>1</sup>, Mohammed-khair Hankir<sup>3</sup>, Sunniyat Rahman<sup>1</sup>, Alan Boobis<sup>1</sup>, and Nabil Hajji<sup>1</sup>

<sup>1</sup>Imperial College London, Centre for Pharmacology and Therapeutics, Department of Medicine, London, United Kingdom;

<sup>2</sup>Departamento de Bioquímica y Biología Molecular. Facultad de Farmacia, Universidad de Sevilla, C/Prof. García González, Sevilla, Spain;

<sup>3</sup>Integrated Research and Treatment Centre for Adiposity Diseases, Department of Medicine, University of Leipzig, Leipzig, Germany

*Key words*: neurotoxicity, Lead, mitochondrial biogenesis and dynamics, PGC-1α, Drp1, BAP3, calcium *Received*: 05/18/14; Accepted: 08/03/15; Published: 09/04/15 *Correspondence to:* Nabil Hajji,PhD; *E-mail:* <u>n.hajji@imperial.ac.uk</u> *Correction*: This article has been corrected. Please see Aging 2015, 2016: <u>https://doi.org/10.18632/aging.100837</u>, <u>https://doi.org/10.18632/aging.100955</u>

**Copyright:** Dabrowska et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

**Abstract:** Due to its role in regulation of mitochondrial function, PGC1 $\alpha$  is emerging as an important player in ageing and neurodegenerative disorders. PGC1 $\alpha$  exerts its neuroprotective effects by promoting mitochondrial biogenesis (MB) and functioning. However, the precise regulatory role of PGC1 $\alpha$  in the control of mitochondrial dynamics (MD) and neurotoxicity is still unknown. Here we elucidate the role of PGC1 $\alpha$  in *vitro* and *in vivo* in the regulatory context of MB and MD in response to lead (II) acetate as a relevant model of neurotoxicity. We show that there is an adaptive response (AR) to lead, orchestrated by the BAP31-calcium signalling system operating between the ER and mitochondria. We find that this hormetic response is controlled by a cell-tolerated increase of PGC1 $\alpha$  expression, which in turn induces a balanced expression of fusion/fission genes by binding to their promoters and implying its direct role in regulation of MD. However, dysregulation of PGC1 $\alpha$  expression through either stable downregulation or overexpression, renders cells more susceptible to lead insult leading to mitochondrial fragmentation and cell death. Our data provide novel evidence that PGC1 $\alpha$  expression is a key regulator of MD and the maintenance of tolerated PGC1 $\alpha$  expression may offer a promising strategy for neuroprotective therapies.

### **INTRODUCTION**

Peroxisome proliferator-activated receptor- $\gamma$  coactivatorl $\alpha$  (PGC-1 $\alpha$ ) is a transcription factor controlling many aspects of oxidative metabolism, including mitochondrial biogenesis, adaptation, respiration, adaptive thermogenesis, gluconeogenesis and oxidative phosphorylation [1, 2]. Signalling for mitochondrial biogenesis (MB) is activated by PGC-1 $\alpha$  and involves the expression of several transcription factors, resulting in the upregulation of proteins encoded by both nuclear and mitochondrial genomes. Oxidative stress from the generation of reactive oxygen species (ROS) has often been cited as toxicants, and is believed to originate from mitochondria. Many neurodegenerative conditions have been shown to originate from compromised number, morphology and function of mitochondria. PGC1 $\alpha$  has previously been reported to play a protective role against neurodegenerative conditions such as Alzheimer's disease and is known to respond to ROS by the induction of many ROS-detoxifying enzymes, including superoxide dismutase, Gpx1and  $\gamma$ -glutamylcysteine, regulating the biosynthesis of glutathione. Moreover, Ca<sup>2+</sup> and ROS have been shown to regulate mitochondrial biogenesis by activating PGC1 $\alpha$ , leading to an increase in mitochondrial mass [3, 4]. Growing evidence suggests that the delicate equilibrium between mitochondrial fission and fusion is vital for many mitochondrial functions including metabolism, energy production,  $Ca^{2+}$  signalling, ROS production and apoptosis. In many types of neurodegenerative diseases, a significant reduction in the levels of fusion proteins optic atrophy-1 (Opa-1), mitofusin-1 (Mfn-1) and mitofusin-2 (Mfn-2) as well as the fission protein dynamin-related protein-1 (Drp-1) is reported, as well as an increase in the level of the fission related protein-1 (Fis-1) [5].

A number of signalling processes relating to mitochondrial, nuclear and inter-organelle communication, have been shown to be sensitive to ROS. Upon oxidative stress, the mitochondria and the endoplasmic reticulum critically contribute to apoptosis induction via a signalling pathway that establishes a feedback loop by releasing  $Ca^{2+}$  from the ER which in turn activates the mitochondria for apoptosis [6].

The majority of mechanisms proposed for neurotoxicant-induced cellular damage converge on mitochondrial dysfunction and energy deprivation [7]. The integrity of this organelle is vital in the context of neurodegeneration due to the high-energy demands of dopaminergic neurons as a result of their unusually long axons [8]. This generates a need for the stringent regulation of mitochondrial biogenesis, function and dynamics in such cells. Disruption of any of these processes can contribute to neurodegenerative disorders [9] such as Parkinson's [10], Alzheimer's [11] and Huntington's disease [12]. However, no study has fully elucidated a link between mitochondrial biogenesis and dynamics in neurotoxicity, highlighting the need for a thorough investigation into PGC1a's role in those processes in the context of neurological disorders.

Chronic exposure to the environmental neurotoxicant lead is believed to be associated with neurodegeneration [13]. While it has been proposed that there is an association between chronic lead exposure and risk of Parkinson's disease (PD) [14, 15], the exact mechanism is not fully understood. Exposure to lead induces oxidative stress in the form of ROS in a variety of different tissues [16, 17] and also induces  $Ca^{2+}$  release from the ER in hippocampal neurons [18]. However, evidence is lacking with regards to the mechanism of neuronal damage and whether its induction in chronically exposed individuals is due to an increased production of ROS or disruption of calcium homeostasis or both.

In this study we investigated the role of PGC1 $\alpha$  as a regulator of both mitochondrial biogenesis and

dynamics in vitro and in vivo in the context of leadinduced neurotoxicity. Strikingly, the role of PGC1a was found to be equivocal. While a modest increase of PGC1a expression provides a neuroprotective role, dysregulation of expression either by knockdown or overproduction is non-tolerated, leading to neurotoxicity. Our data showed a significant increase of expression of a mitochondrial fission protein, DRP1, in both, neurons in the rat substantia nigra (SN) and adopaminergic (DA) neuronal N27 cell line. SN cells showed an adaptive response to lead exposure by increasing the transcript levels of PGC1 $\alpha$ , its target genes, regulating mitochondrial biogenesis, and mitochondrial fusion- and fission-related genes. ChIP and QPCR analysis revealed that PGC1a directly regulates DRP1expression by binding to its promoter. Our data provides strong evidence that PGC1a is directly involved in the cellular response to lead by regulating mitochondrial dynamics.

# RESULTS

### Exposure to lead induces mitochondrial dysfunction, energy depletion and subsequent apoptosis of dopaminergic neurons

N27 cells, derived from rat mesencephalon, were used to evaluate the effect of lead on mitochondrial function. Cells were treated with a range of lead (II) acetate concentrations over a period of 48 hours. Cells stained with MitoSOX and analyzed by flow cytometry revealed a 25% increase in mitochondrial superoxide at 5 µM and 100 µM concentrations and almost a 100% increase at 500 µM (Fig. 1A). DiOC<sub>6</sub>(3), a selective mitochondrial dye, and propidium iodide (PI) staining revealed that lead causes mitochondrial membrane depolarization and neuronal cell death, which was much more marked at 500  $\mu$ M than at 5 or 100  $\mu$ M (Fig. 1B, C). PARP cleavage analysis (Fig. 1D) confirmed this, with the effect being far more pronounced at the highest lead concentration. At 5µM and 100µM, effects on mitochondrial dysfunction and cell death were similar (Fig. 1A-D). Apoptotic cell death was confirmed by an increased activation of caspases3/7 and caspase 8 in N27 cells exposed to 100µM and 500µM lead (Supplementary Figure 1-S-1, A-a and b). Morphological characteristics of apoptotic cells, including condensed nuclei, were also evident in cells treated with 500µM lead (Supplementary Figure1-S-1, B and C). Morphological changes in the cells were apparent only at higher concentrations than changes in molecular markers of apoptosis, most likely reflecting the temporal engagement of the respective hallmarks of apoptosis.

Mitochondrial function was assessed by *Seahorse XF24* analysis allowing for the measurement of a number of parameters including mitochondrial basal respiration, ATP production, oxygen consumption rate (OCR), maximum respiratory capacity and mitochondrial spare respiratory capacity. While a reduction in basal respiration was observed in cells treated with 100 and 500  $\mu$ M lead (Fig. 1E), this was not statistically significant. There was a concentration-dependent decrease in ATP production (Fig. 1F), with the highest

lead concentration causing a statistically significant (P<0.01) decrease of more than 50%. Proton leak was not significantly affected by lead treatment (Fig. 1G). Maximal respiration decreased in a concentration-dependent manner (Fig. 1H). Interestingly, mitochondrial reserve capacity levels were very low across all of the lead-treated cells (P<0.01) including 5  $\mu$ M, a concentration which did not have a significant impact on other aspects of mitochondrial function investigated with the Seahorse XF24 compared with control (Fig. 1I).



**Figure 1. Exposure to lead induces mitochondrial dysfunction and subsequent apoptosis of N27 dopaminergic neurons.** Cells were incubated for 48-hours with lead acetate, at the concentrations shown. (A) Mitochondrial superoxide levels were measured using MitoSOX staining followed by FACS analysis. (B) The effect of lead treatment on mitochondrial membrane potential (MMP) loss was detected by  $DiOC_6(3)$ . (C) Analysis of cell death measured by propidium iodide (PI). (D) Western blot analysis of PARP cleavage (PARP to PARPc) following lead exposure. Profiles of different parameters of mitochondrial function (E-I) were determined using Seahorse XF24 Analyser. \**P*<0.05, \*\**P*<0.01, \*\*\**P*<0.001, n=3; mean ± SE.



**Figure 2. PGC1a protects N27 dopaminergic neuronal cells from Pb<sup>2+</sup>-induced neurotoxicity.** Cells were incubated with lead acetate at the concentrations shown. (**A**,**B**) qRT-PCR and western blotting measurement of mRNA and protein expression levels, respectively of *Pgc1a* in N27 cells treated with lead for 48-hours. (**C**) mRNA levels of *Pgc1a* target genes (*Tfam, Nrf1*)inN27 cells treated with lead for 48-hours.(**D**)N27 *Pgc1a*mRNA levels after 3-hours lead treatment.(**E**) *Pgc1a* mRNA levels and (**F**) colony formation in N27 cells with stable downregulation of PGC1a. (**G**) Mitochondrial superoxide levels were measured in shPGC1a cells using MitoSOX staining and (**H**) the effect of lead treatment on mitochondrial membrane potential loss in shPGC1a was detected by DiOC<sub>6</sub>(3) in N27 cells treated with lead for 48-hours. (**I**, **K**) Confocal imaging analysis of mitochondrial morphology in wild type PGC1a and in overexpressed PGC1a N27 cells (*^Pgc1a*) was investigated using Mito Tracker and DAPI staining recorded by fluorescence microscopy. (**J**) qRT-PCR analysis of *Pgc1a* versus *^Pgc1a* cells, treated with lead for 48-hours.\**P*<0.05, \*\**P*<0.01, n=3; mean ± SE.

# PGC1α protects DA neurons from neurotoxic insults from lead

Real-time QPCR and protein expression analyses were performed to investigate the expression of Pgcla and its downstream targets, which regulate mitochondrial biogenesis, in lead-treated N27 cells. Interestingly, only the 100 µM treatment with lead for 48 h caused a significant increase of Pgcla expression, at both the RNA and protein levels (Fig. 2A, 2B). Downstream targets of PGC1a, Tfam and Nrf1 showed a similar pattern of expression, with changes apparent only at 100 µM lead (Fig. 2C). In order to determine whether the highest lead concentration affects Pgc1a expression at an early exposure time point, Pgcla mRNA levels were investigated after a 3-hour lead exposure. Surprisingly, the expression of Pgcla mRNA levels was markedly upregulated 3-hour post-treatment, with a ten-fold increase observed at 500 µM (Fig. 2D).

Since no significant difference was observed between cells treated with 5  $\mu$ M and 100  $\mu$ M in terms of disruption of mitochondrial function, ROS generation or cell death(Fig. 1A-D), but there was a significant difference in Pgc1a mRNA levels between the two groups, we sought to investigate whether  $Pgcl\alpha$  plays a protective role against lead insult at 100 µM. To interrogate this hypothesis, we produced a stable knockdown of Pgcla using a lentiviral shRNA vector. Successful knock-down was confirmed by Pgcla mRNA levels (Fig. 2E) and clear downregulation of PGC-1a protein levels, as shown by immunocytochemistry (Supplementary Figure 3-S3, A). sh-PGC1a transduction did not affect colony formation (Fig. 2E and F). FACS analysis of cells stained independently with MitoSOX and  $DiOC_6(3)$  showed that reduction of  $Pgcl\alpha$  expression renders N27 cells more susceptible to lead-induced mitochondrial stress (Fig. 2G, H), with morphological characteristics of apoptosis apparent in 100µM cells treated with or 500µM lead (Supplementary Figure 1-S1, B).

The influence of lead treatment on mitochondrial organisation was investigated by immunofluorescence (Fig. 2I). Exposure to 100  $\mu$ M lead caused mitochondrial filament elongation, while mitochondria in cells exposed to 500  $\mu$ M Pb<sup>2+</sup> were very fragmented and localized to the nuclear perimeter (Fig. 2I).

# An equivocal role of PGC1 $\alpha$ in neuroprotection and toxicity

To determine whether up-regulation of  $PGC1\alpha$  was responsible for the changes in mitochondrial morphology and organization and subsequent protection

of DA neurons from lead insult, we examined the effects of PGC1a overexpression on the structure of mitochondria (Fig. 2J and K) and (Fig. 3A and B). Intriguingly, overexpression of PGC1a actually increased susceptibility of N27 cells to lead toxicity at both 100 and 500 µM, as manifested by increased fragmentation of mitochondria, measured as a decrease in mitochondrial surface area (Fig. 3A and B). Whereas a two-fold increase in PGC1a expression protected cells against lead-induced neurotoxicity (endogenous levels of the protein doubled in response to 100 µM lead), higher expression levels (>50 fold) of the protein had the opposite effect and exacerbated the toxicity of lead (Fig. 2J and K). Furthermore, cells overexpressing PGC1a treated with 100µM and 500µM leaded showed condensed nuclei. apoptotic hallmark an (Supplementary Figure1-S1, C).

Since exposure to lead induced changes in mitochondrial organization, the expression profiles of genes encoding proteins regulating mitochondrial dynamics were investigated. RT-OPCR analysis revealed that 100 µM lead shifts the mitochondrial dynamic profile towards fusion (Fig. 3C). While Mfn2 mRNA levels were increased, the transcript levels of Drpl, a fission promoting factor, were significantly decreased upon treatment. The Fis1 mRNA expression profile remained unchanged. To investigate the role of PGC1α alone in regulation of mitochondrial dynamics, Drp1 and Mfn1 expression levels were investigated in PGC1a-overexpressing cells. Levels of Mfn1 expression mRNA) were significantly increased whilst those of Drp1 were significantly decreased (mRNA and protein) (Fig. 3D and Supplementary Figure 3-S3, B).

This suggested that overexpression of PGC1 $\alpha$  was accompanied by a shift of the mitochondrial dynamics profile towards fusion (Fig. 3D). ChIP assay was performed to identify regulatory targets of PGC1 $\alpha$ . This revealed significantly increased binding of PGC1 $\alpha$  to its own promoter and unexpected binding to the *Drp1* promoter (Fig. 3E). Moreover, PGC1 $\alpha$  bound to *Nrf1* and *SOD2* promoters.

In order to compare the effect of lead on neuronal cells *in vitro* and *in vivo*, tissue samples were obtained from substantia nigra of rats given drinking water containing 500 ppm lead acetate for a period of 14 weeks as well as from control animals given water with acetate only. Real time QPCR analysis showed that Pgc1a mRNA levels, as well as levels of its downstream targets (*Nrf1*, *Nrf2*, *Tfam*) were significantly increased in the substantia nigra of animals exposed to lead (Fig. 4A). Expression of both mitofusins was also significantly induced by lead (Fig. 4A). Interestingly, unlike N27

dopaminergic neurons exposed to lead for 48-hours *in vitro*, levels of the*Drp1* transcript were increased together with levels of *Mfn1* and *Mfn2* transcripts, after lead exposure *in* vivo, with no decrease in the number of tyrosine hydroxylase-expressing, dopaminergic SN neurons cells (Fig. 4B and C). Since SN tissue used in the experiment was a heterogeneous mixture of different cell types, including neurons, we performed dual fluorescence immunohistochemistry of DRP1 and NeuN (a neuronal specific marker) in the ventral mesencephalon to determine whether the previously observed increase

in Drp1 expression was specific to DA neurons (Fig. 4D). Further analysis confirmed that the expression of DRP1 protein was significantly induced by lead in SN pars compact a neurons only (Fig. 4E). As adult rats are less susceptible to lead toxicity than young rats, and a significant increase of Drp1 expression was observed *in vivo* at 48-hours, we looked at Drp1 expression *in vitro* after short-term exposure (Fig. 4F). After 3-hours of lead exposure in N27 cells, an elevation of Drp1 mRNA levels was observed (P<0.01).



**Figure 3. Lead-induced changes in mitochondrial morphology and dynamics.** Immunocytochemistry and confocal imaging analysis of N27 cells co-transfected with an empty vector and mitoYFP (**A**, a-c) or PGC1 $\alpha$ -encoding vector and mitoYFP (**A**, d-f). The extent of the mitochondrial network both under basal conditions (a), Pb<sup>2+</sup> 100 $\mu$ M (b), Pb<sup>2+</sup> 500 $\mu$ M (c) and PGC1 $\alpha$  overexpression alone (d) or combined with Pb<sup>2+</sup> 100 $\mu$ M (e) or 500  $\mu$ M (f) was measured by Spectrum. (**A**, a'-f') mitochondrial area surface determined using ImageJ->threshold->Intermodes,(B,W). (**B**) Mitochondrial surface area in cells was determined using ImageJ software.(**C**) N27 cells treated with 100 $\mu$ M lead for 48-hours were analysed for the expression of mitochondrial fusion (*Mfn2*) and fission (*Drp1*, *Fis1*) genes by qRT-PCR. (**D**) qRT-PCR analysis of the expression of *Drp1* and *Mfn1* in PGC1 $\alpha$  overexpressing cells.(**E**) Chromatin immunoprecipitation (ChIP) with a PGC1 $\alpha$  antibody was performed to investigate PGC1 $\alpha$  protein binding to its promoter, Nrf1, Drp1 and SOD2 gene promoters,\**P*<0.05, \*\**P*<0.01, \*\*\**P*<0.001, n=3; mean ± SE.



Figure 4. *In vivo* sub-lethallead concentration in drinking water increases the expression of genes controlling mitochondrial biogenesis and dynamics. Adult rats received drinking water containing 500 ppm lead acetate for 14 weeks and control animals received water with acetate only. Substantia nigra tissue was isolated and mRNA was extracted and processed for Real time QPCR analysis. (A) mRNA levels of *Pgc1a* and its target genes *Nrf1*, *Nrf2* and *Tfam* as well as*Mfn1*, *Mfn2*and *Drp1* were analysed by qRT-PCR; (B) Immunohistochemistry was performed to detect tyrosine hydroxylase (TH) positive neurons and (C) stereological counting of TH-positive neurons in the substantia nigra of rats given drinking water containing 500 ppm lead acetate for 14 weeks. (D) Immunohistochemistry of DRP1 and NeuN co-localisation in the ventral mesencephalon neuronal cells. (E) Drp1 signal intensity was analysed by confocal laser scanning microscope (Zeiss LSM 7 DUO), using the associated software package (ZEN 2010) and quantified using an Image Analysis Program from Soft Imaging System (analySIS<sup>®</sup>, Germany). (F) *MfnI* and *Drp1* mRNA levels in N27 cells after 3-hours of lead exposure. \**P*<0.05, \*\**P*<0.01, \*\*\**P*<0.001, n=6 (F, n=3); mean ± SE.



**Figure 5. Lead treatment causes a disruption of cellular calcium balance.** Pre-treatment of N27 cells with 1 mM N-acetylcysteine (NAC) for 1 hour followed by a 48-hours lead-exposure was used to investigate the impact on mitochondrial ROS (A) and mitochondrial depolarisation (MMP) (B) N27 cells treated with lead for 48-hours were tested for cytoplasmic (C) and ER calcium levels (D) using thapsigargin (Tg) and Rhod-2 staining followed by flow cytometry analysis (D, a and b). Calcineurin transcript levels 48-hours post-lead exposure were investigated using qRT-PCR (E). Pre-treatment of N27 cells with 5 $\mu$ M BAPTA-AM for 1 hour followed by a 48-hours lead-exposure was used to investigate the impact of calcium on mitochondrial depolarisation (F) and cell death (G) following lead treatment. (H) Western blot of BAP31 protein levels after 48-hours lead treatment. (I) Western blot analysis of BAP31 levels in shBAP31 N27 cells. N27 cells with stable downregulation of BAP31 (shBAP31) were used to investigate the involvement of BAP31 in lead-induced mitochondrial superoxide generation (J), mitochondrial depolarisation (MMP) (K) and activation of caspases 3/7 (L) and 8 (M). \**P*<0.05, \*\**P*<0.01, \*\*\**P*<0.001, n=3; mean ± SE.

# Lead treatment causes a disruption of cellular calcium balance

The possible role of ROS in lead-induced cell death in N27 cells was investigated using N-acetylcysteine (NAC), a well-known ROS scavenger. However, NAC pre-treatment of cells had no effect on lead-induced changes in mitochondrial ROS or membrane potential (Fig.5A and B). Therefore, we explored the possibility that changes in intracellular Ca<sup>2+</sup> levels might mediate the effects of lead, since lead is known to mimic this cation inside the cell and compete with it for binding to Ca<sup>2+</sup>-dependent proteins. Moreover, calcium-regulated proteins have been shown to play a role in control of PGC1 $\alpha$  expression [19].

Staining of cells with Fluo4-AM, a cytoplasmic calcium dye, revealed that lead causes an increase of cytosolic Ca<sup>2+</sup> with depletion within the ER (Fig. 5C and D). Pretreatment of cells with BAPTA-AM, a cytoplasmic calcium chelator, conferred protection against lead insult (Fig. 5F and G). This finding, together with a lack of response to NAC on cellular susceptibility to lead, implicates a primary role for calcium in the response of dopaminergic neurons to lead. mRNA levels of calcineurin, a modulator of a number of key Ca2+ signalling pathways in neurons, were significantly increased on exposure to higher concentrations of lead, with peak expression occurring at 100  $\mu$ M (Fig. 5E). Calcineurin mRNA levels at 100 µM and 500 µM mirrored those of Pgc1a and its target genes Nrf1 and Tfam (Fig 1A-C).

Caspase-8 cleavage of BAP31 at the ER stimulates  $Ca^{2+}$ -dependent mitochondrial fission and subsequently enhances pro-apoptotic signals between the ER and mitochondria [6, 20]. Since the protein level of BAP31 increased after exposure to 100µM and 500µM lead (Fig. 5H), we investigated whether BAP31 down-regulation had any neuroprotective effect against lead insult. shRNA delivered by a lentiviral vector was used to knock down *Bap31* expression in N27 cells (Fig. 5I).shRNA-*Bap31* conferred significant protection against lead toxicity (Fig. 5J-M) implying an important role of BAP31 in the response to lead and in calcium pathway regulation.

# **DISCUSSION**

In this study, we demonstrate for the first time that  $PGC1\alpha$  regulates both mitochondrial biogenesis and dynamics in dopaminergic neurons exposed to neurotoxic lead (II) acetate. Despite a 20-fold concentration difference between 5µM and 100µM, the effects of lead acetate on mitochondrial superoxide

membrane generation and polarization were comparable. As both of these concentrations exhibited minimal toxicity, they were classified as tolerated. However, at 500 µM, lead had a much more deleterious effect on mitochondrial function and subsequently induced excessive cell death: therefore this concentration was classified as toxic. Interestingly, while most parameters of mitochondrial function remained unaffected by tolerated concentrations of lead, spare respiratory capacity (SRC) was lost at all concentrations, a previously unreported effect of lead. This finding is consistent with the stochastic mitochondrial failure model proposed by Choi, et al. [21] to explain the importance of mitochondrial SRC in neurodegeneration. SRC is used here to describe the amount of extra ATP that can be produced by oxidative phosphorylation in case of a sudden increase in energy demand. Depletion of the SRC has been related to a range of pathologies affecting high energy requiring cells such as neurons [21, 22].

As N27 cells were able to tolerate concentrations of lead up to a toxic threshold, we suspected the presence of a protective mechanism, to help cells survive lead insult. PGC1 $\alpha$  is a well-established master regulator of mitochondrial metabolism [1] and has previously been reported to play a protective role against a variety of neurodegenerative conditions [23, 24]. PGC1a is also known to respond to ROS by inducing a cellular ROS scavenging program [25]. Due to these diverse functions, we investigated whether PGC1 $\alpha$  plays a role in the cellular response to lead exposure. Exposure of cells to 100 µM lead for 48-hours indeed resulted in increased expression of PGC1a and modulation of its downstream targets, including genes regulating mitochondrial biogenesis. Stable down-regulation of Pgcla expression in DA cells increases their vulnerability to lead insult. Thus, we show for the first time that exposure to sub-lethal doses of lead induces low-level stress, which triggers an adaptive response mediated by PGC1a. This supports the hypothesis that PGC1 $\alpha$  acts to protect the cells by promoting mitochondrial biogenesis, boosting their function and suppression of ROS [26]. We believe that at low lead levels, slightly increased ROS production, which acts as a retrograde nuclear signal, can improve mitochondrial function with adaptation to the stressor, a phenomenon known as mitohormesis [27].

Short exposure (3-hours) to lead induces a significant increase of  $Pgc1\alpha$  transcript levels at 100µM and 500µM. However, whereas at 100µM the increase is sustained at 48-hours, at 500 µM, levels return completely to baseline by this time. Hence, lead modulates  $Pgc1\alpha$  expression in a dose-and time-

dependent manner. At toxic doses the adaptive response of the cell is initially triggered but becomes overridden by the excessive toxicity, such that it is beyond the homeostatic ability of the cell to counteract the insult. Unexpectedly, overexpression of Pgcla did not confer increased protection against lead, instead, upon treatment with lead, cells showed an increased level of apoptosis compared with wild-type cells. Thus, the role of PGC1a appears to be equivocal: while it helps the cell to tolerate a certain level of toxic insult, prolonged expression to non-physiological levels has a deleterious effect on mitochondrial function and viability of the cells. Ciron et al.[28] have previously shown that sustained expression of PGC1a in dopaminergic neurons leads to neurodegeneration. Therefore, we postulate that PGC1a plays a dual role in response to the neurotoxicant lead. Increased expression at lower concentrations of lead is beneficial as part of an adaptive, mitohormetic response, whereas at higher concentrations, higher expression levels of PGC1a, when sustained for a prolonged period of time, characteristic of chronic exposure, lead to lethal changes in cellular metabolism.

We have observed that changes in the expression of PGC1a result in a structural alteration of mitochondrial filaments. There has been little research investigating the role of PGC1a in orchestrating mitochondrial dynamics. Previously it has been suggested that PGC1a promotes mitochondrial fusion via co-activation of MFN2expression [29]. Moreover, it has recently been shown that PGC1 $\alpha$  regulates MFN1. Martin et al.[30]also showed an association between PGC1 $\alpha/\beta$ levels and expression of other fission/fusion genes. However, these authors did not explore the direct interaction between PGC1 proteins and the genes mentioned above. Therefore we investigated the expression of a range of genes known to control mitochondrial dynamics, upon exposure to lead. In this study, we made the novel observation of a PGC1ainduced decrease in DRP1 expression in vitro, in addition to increased levels of MFN2 transcript. It appears that the shift of mitochondrial dynamics towards fusion, observed at 100 µM lead, is due to a change in the transcriptional profile of a number of genes controlling this process. A similar effect was seen in cells overexpressing PGC1 $\alpha$ , confirming the role of this transcriptional co-activator in the control of mitochondrial dynamics. While in vivo data supported the notion of lead increasing the expression of mitofusins (MFN1 and MFN2), and so, promoting fusion, we also observed an increase of Drp1 mRNA. Since substantia nigra obtained from rats, as used in our experiments, is a heterogeneous mixture of different cells with dopaminergic neurons comprising just 1-2%

of the total cell population [31], we looked at colocalization of NeuN and DRP1 in samples to exclude the possibility that the global SN mRNA changes observed in our experiment interfere with measurements of the transcriptional state of dopaminergic neurons.

Having confirmed that Drp1 levels are increased in SN neurons, we sought to match an appropriate exposure duration *in vitro*. Hence, the expression profile of this gene was determined in N27 cells following a short 3-hours exposure to 100  $\mu$ M lead. Drp1 expression was increased after this time, but reduced after 48-hours. Hence, this short exposure *in vitro* could be reflecting an early event that happens in DA neurons as protection against lead exposure.

ChIP data revealed that PGC1 $\alpha$  binds to the promoter of *Drp1* implying its direct role in regulating the expression of this mitochondrial protein. We propose that as an initial response to the insult *in vivo* and *in vitro*, PGC1 $\alpha$  levels increase in response to lead, which promotes mitochondrial biogenesis. This in turn requires an increased expression of proteins regulating mitochondrial dynamics. Tight control of this vital process is essential to maintain balanced intracellular energy distribution and cell viability.

Continuous exposure to tolerated level of lead triggers a protective response which involves a non-excessive expression of genes regulating mitochondrial dynamics with the shift of the balance toward fusion, which has been previously shown to help protect against neurodegeneration [32]. We believe that while the binding of PGC1 $\alpha$  to the promoter of *Drp1* at lower concentrations (100 $\mu$ M) results in an increase in the expression of DRP1 to ensure maintenance of fusion-fission balance in the cell, the transcript levels of *Drp1* remain low at high lead concentrations due to the absence of other members of a transcription complex driving expression of this gene, lack of transactivation or presence of an inhibitor, such as e.g. p160<sup>MYB</sup> [33].

Whilst evidence was obtained that demonstrates PGC1 $\alpha$  plays a pivotal role in the response of DA cells to lead, it was unclear the mechanisms by which lead and PGC1 $\alpha$  are inter-linked. One possibility was ROS. However, the antioxidant NAC was unable to prevent an increase in lead-induced mitochondrial ROS and subsequent loss of mitochondrial membrane potential. We then focused on calcium, a ubiquitous intracellular secondary messenger. Calcium is of particular interest due to the ability of lead to mimic this ion in the cellular milieu [34]. In the present study, we show that lead causes release of ER calcium stores, increase in cytoplasmic calcium concentrations, which cause

disruption of calcium balance leading to mitochondrial dysfunction and DA neuronal cell death. Interestingly, calcineurin, the activity of which depends on  $Ca^{2+}$ /calmodulin binding, can be activated by low concentrations of free lead while higher concentrations reduce its activity [35]. Our data showed a significant increase in calcineurin transcription levels at a tolerated concentration of lead (100µM) and a clear decline at the toxic concentration (500 µM), an observation consistent with the published data.

Disruption of ER calcium stores has previously been implied in neurodegeneration [36] and has been suggested as one of the mechanisms via which lead causes cognitive dysfunction in neonatal rats [18]. Unlike NAC, pre-treatment of dopaminergic cells with the calcium chelator BAPTA-AM prevented leadinduced mitochondrial membrane potential loss and subsequent cell death, reflecting the upstream role played by this ion in lead toxicity. ER calcium is linked to apoptosis by pro-apoptotic Bap20, the cleavage product of ER-localized BAP31, which mediates mitochondria-ER cross talk through a Ca<sup>2+</sup>-dependent mechanism [37]. Our data showed that stable knockdown of BAP31 significantly decreases activation of caspase-8 as well as caspase 3/7. Caspase-8 cleavage of BAP31 at the ER stimulates Ca<sup>2+</sup>-dependent mitochondrial fission, enhancing cell death [38].



Figure 6. Schematic representation of adaptive response and neuroprotection induced by celltolerated levels of Pb2+. Exposure to non-cytotoxic levels of lead ( $100\mu$ M) induces an adaptive biological response. This response involves ER calcium release and requires both caspase-8 activation and BAP31 cleavage (1). Increased cytoplasmic levels of calcium induce expression and activation of calcineurin (2) as well as an increase in PGC1 $\alpha$  expression. Subsequently, PGC1 $\alpha$  stimulates its own expression and the expression of mitochondrial biogenesis (*NRF1*, *NRF2*, *TMFA*) and dynamics (*DRP1*and *MFN1*) genes (3). A shift of mitochondrial dynamics towards fusion renders neuronal cells more resistant to lead insult (4-5).

Interestingly, Breckenridge and co-workers [38]have shown that overexpression of Bap20 causes ER Ca<sup>2+</sup> release and concomitant uptake of Ca2+ into mitochondria with subsequent recruitment of DRP1, resulting in dramatic mitochondrial fragmentation. Our data show that the BAP31 protein increases in a dose dependent manner with lead exposure and its knockdown reduces lead-induced initiation of the mitochondrial cell death pathway. This reveals the important role played by this ER protein in disruption of calcium homeostasis in response to lead insult. Together, our data and those of Brekenridge and coworkers strongly suggest the involvement of ER calcium and DRP1-controlled fission in response to lead exposure.

# CONCLUSIONS

We show for the first time that low levels of lead cause disruption of cellular calcium balance in dopaminergic neurons, involving BAP31-mediated ER-mitochondrial crosstalk, which induces an adaptive response mediated by PGC1a. This effect involves an alteration of expression of genes regulating mitochondrial dynamics (shown by us to be controlled by PGC1 $\alpha$ ). We have also made the novel discovery that PGC1 $\alpha$  is directly involved in control of Drp1 expression (Fig. 6). While beneficial and protective at physiological levels, it appears that long term, chronic stimulation of cells at higher concentrations of lead causes sustained expression of PGC1 $\alpha$  at high levels, leading to neurodegeneration via profound remodeling of the mitochondrial network and changes in cellular metabolism. Moreover, any homeostatic imbalance in PGC1a levels (downregulation/overexpression) renders DA cells more susceptible to lead insult. We have also shown that lead causes loss of SRC which renders the cells more susceptible to degeneration when subject to an increased energy demand.

This study provides evidence that the maintenance of a homeostatic PGC1 $\alpha$  expression level is essential for protection of neuronal cells against lead insult.

# **MATERIALS AND METHODS**

<u>Cell culture and treatments.</u> Rat mesencephalon-derived cell line (1RB<sub>3</sub>AN<sub>27</sub>; hereafter referred to as N27 cells)represent a homogenous population of tyrosine hydroxylase-expressing cells with functional characteristics resembling dopaminergic neurons. N27 cells were maintained in RPMI-1640 medium supplemented with 10% FBS, 100 U/ml penicillin and 100  $\mu$ g/ml streptomycin (Sigma) at 37°C in a 5% CO<sub>2</sub> humidified atmosphere. Cells were exposed to lead (II) acetate (Sigma) dissolved in distilled water added to the growth medium at 5, 100 and 500  $\mu$ M for 48-hoursor 3-hours, as indicated.

<u>Stable cell line production.</u> The pLKO.1-TRC cloning vector was obtained from AddGene. Oligonucleotides containing shRNA were cloned into the vector according to the manufacturer's protocol. For shRNA primers used for PGC1 $\alpha$  and BAP31 see Supplementary Material Table 1.

Virions were produced in HEK293T cells, by combining three packaging plasmids (pVSV-G), pRev, pGag.Pol (Invitrogen) with pAdVantage (Promega), and pLKO vector. Water and 2 M CaCl<sub>2</sub> were added and complexes were mixed with  $2 \times$  HBS (500 µl) and added to cells drop wise. After an overnight incubation, fresh DMEM medium containing 1 mM sodium butyrate was added. Post-transfection the supernatant was collected, spun down and filter-sterilized. N27 cells were transduced for 8-hours in the presence of polybrene (Sigma). Cells were selected with puromycin 3 days after transduction.

Successful knockdown was confirmed by the reduction in specific mRNA (Fig. 2E and protein, as determined immunocytochemically (Supplementary figure 3-S3, A).

<u>Caspase activity measurement.</u> Caspase activity assays were performed using CaspaTag<sup>TM</sup> caspase-3/7 or 8 assay kit (Millipore) according to the manufacturer's protocol followed by data collection with FACSCalibur<sup>TM</sup> (BD Biosciences) and analysis with Cyflogic (CyfLo Ltd.)

Mitochondrial superoxide measurement. Mitochondrial superoxide levels were measured using MitoSOX<sup>TM</sup> Red (Invitrogen) according to the manufacturer's guidelines. FACSCalibur<sup>TM</sup> (BD Biosciences) was used for data collection and Cyflogic (CyfLo Ltd.) for the analysis.

<u>Mitochondrial membrane depolarisation.</u> Cells were harvested as described above and resuspended in 150  $\mu$ l of PBS containing 40 nM 3,3-dihexaoxacarbocyanine iodide (DiOC6) and PI (50  $\mu$ M) for 40 minutes at 37°C. Cells were then analysed using FACSCalibur<sup>TM</sup>.

<u>RNA extraction from cells.</u> Total RNA extraction was performed using QiaShredder columns and the RNeasy extraction kit (Qiagen).

<u>Animals and surgery.</u> Twenty male albino Wistar rats (250-270 g) were kept at constant room temperature of  $22 \pm 1$  °C and relative humidity (60%) with a 12-h light-

dark cycle (8:00 a.m.-8:00 p.m.), with free access to food and water containing either sodium lead acetate (500 ppm) or sodium acetate for 14 weeks. Then, half of the animals in each group were killed by decapitation (RT-PCR experiments) or by perfusion (immunohistochemistry experiments).

Fluorescence immunohistochemistry. Thaw-mounted 20- $\mu$ m coronal sections were cut on a cryostat at -15 °C and mounted in gelatin-coated slides. For doublelabelling of DRP1 with NeuN, sections were blocked with PBS containing 1% normal goat serum and horse serum (Vector) for 1 h. The slides were washed three times in PBS and then incubated overnight at 4°C with either rabbit-derived anti-DRP1 (1:300; Cell Signalling) or mouse-derived anti-NeuN (1:1000; Millipore) diluted in PBS containing 1% normal goat/horse serum and 0.25% Triton X-100. Sections were incubated with goat anti-rabbit secondary antibody conjugated to fluorescein (1:200, for DRP1; Vector) and horse anti-mouse secondary antibody conjugated to Texas Red (1: 200, for NeuN; Invitrogen) for 1 h. Nuclei were counterstained with Hoechst  $(1 \ \mu g \ ml^{-1})$ , Molecular Probes). Fluorescence images were acquired using a confocal laser scanning microscope (Zeiss LSM 7 DUO) and processed using the associated software package (ZEN 2010). Signal intensity was quantified using an Image Analysis Program from Soft Imaging System (analySIS®, Germany).

#### Stereological counting of TH-positive neurons in SN.

The number of TH-positive neurons in the SN was estimated using a fractionator sampling design. Counts were made at regular predetermined intervals (x = 150 $\mu$ m and y = 200  $\mu$ m) within each section. An unbiased counting frame of known area ( $40 \times 25 \ \mu m = 1000 \ \mu m^2$ ) was superimposed on the tissue section image under a 100× oil immersion objective. Therefore, the area sampling fraction is  $1000/(150 \times 200) = 0.033$ . The entire z-dimension of each section was sampled; hence, the section thickness sampling fraction was 1. In all animals, 20-µm sections, each 100 µm apart, were analyzed; thus, the fraction of sections sampled was 20/100 = 0.20. The number of neurons in the analyzed region was estimated by multiplying the number of neurons counted within the sample regions by the reciprocals of the area sampling fraction and the fraction of section sampled[39].

<u>RNA extraction from tissue.</u> Rat substantia nigra were dissected with reference to a standard rat brain atlas (Paxinos and Wilson, 6<sup>th</sup> Edition, Elsevier), immediately snap-frozen in liquid nitrogen and stored at -80C. Total RNA was extracted using the phenolchloroform method. Ice-cold Trizol reagent (Life Technologies) was added to 25-50mg of sample according to the manufacturer's instructions. Brain tissue kept on ice was homogenized using a tissue homogenizer (OMNI international).

<u>Real-time PCR.</u> Five  $\mu$ g RNA was used to synthesize cDNA using the ThermoScript<sup>TM</sup> RT-PCR first strand synthesis system (random hexamer method) according to manufacturer's instructions (Invitrogen). Platinum SYBR Green qPCR Super Mix-UDG (Invitrogen) was used for qPCR analysis. Primers were designed using Primer Blast (supplementary data, table 1). Real time PCR reactions were performed using Stratagene Mx3000P instrument. MxPro Software (Stratagene) was used to obtain Ct values. Transcript levels relative to GAPDH were determined using the standard curve method.

<u>Mitochondrial function assessment.</u> The Seahorse XF analyzer was used according to manufacturer's guidelines (Seahorse Bioscience). OCR values were measured by XF24 extracellular flux analyzer.

Immunocytochemistry. Cells were stained with MitoTracker Red (Molecular probes) according to the manufacturer's fixed 4% protocol, with paraformaldehyde and blocked in 10mM HEPES, 0.3% TX-100, 3% BSA, pH 7.4 for 1 hour at RT. Coverslips were subsequently incubated with PGC1 $\alpha$  antibody (overnight; Everest) and AlexaFluor 488 anti-goat IgG secondary antibody (RT, 1 h; Molecular Probes). Nuclei were counterstained with Hoechst (Molecular Probes).

<u>Western blot analysis.</u> Cells were homogenized on ice in lysis buffer (1 M Tris-HCL, 2.5 M NaCl, glycerol, 0.5 M  $\beta$ -glycerophosphate, Tween 20 and Nonidet P40). The lysate was cleared by centrifugation at 900 g for 10 min at 4 °C. 50-120  $\mu$ g of proteins were run on a 10% SDS-PAGE gel and transferred to nitrocellulose membranes (GE healthcare). Membranes were blocked with 5% non-fat dry milk dissolved in PBS with 0.01% Tween 20 (Sigma). Incubation with primary antibodies was performed overnight at 4°C (see supplementary materials for the antibody list). Peroxidase activity was developed using enhanced chemiluminescence (ECL).

<u>Chromatin immunoprecipitation.</u> N27 cells were treated and fixed with formaldehyde and quenched with glycine. Chromatin immunoprecipitation of samples was performed as described previously [40] using PGC1 $\alpha$  antibody, followed by Q-RT-PCR analysis. An irrelevant goat antibody (IgG) was used as a negative control, to control for the possibility of non-specific clumping of chromatin. C<sub>t</sub> values were normalized according to the following equation:  $\Delta C_t$ [normalized ChIP] = (Ct[ChIP] – (Ct[input] – log<sub>2</sub> (0.1))). The % input was calculated with the following equation: % input =  $2^{(-\Delta Ct[normalised ChIP])}$ . For the list of target promoter primer pairs see supplementary materials. PGC-1 $\alpha$ binding sites were all within promoter regions, defined as ±3 kb from a transcriptional start site (TSS). (Please see supplementary figure 3-S3, C).

#### ACKNOWLEDGENENTS

We gratefully acknowledge Dr. Miguel Angel Burguillos and Dr. Lucien West for their critical and constructive comments.

#### Funding

This work was supported by a studentship from the Medical Research Council (MRC) and grant from Spanish Ministerio de Economía y Competitividad (SAF2012-39029).

#### **Conflict of interest statement**

The authors do not have any conflict of interest to declare.

### **REFERENCES**

**1.** Austin S, St-Pierre J. PGC1alpha and mitochondrial metabolism--emerging concepts and relevance in ageing and neurodegenerative disorders. J Cell Sci. 2012; 125:4963-4971.

**2.** Uguccioni G, Hood DA. The importance of PGC-1alpha in contractile activity-induced mitochondrial adaptations. Am J Physiol Endocrinol Metab. 2011; 300:E361-71.

**3.** Sano M, Fukuda K. Activation of mitochondrial biogenesis by hormesis. Circ Res. 2008; 103:1191-1193.**4.** Ojuka EO, Jones TE, Han DH, Chen M, Holloszy JO. Raising Ca2+ in L6 myotubes mimics effects of exercise on mitochondrial biogenesis in muscle. FASEB J. 2003; 17:675-681.

**5.** Su B, Wang X, Zheng L, Perry G, Smith MA, Zhu X. Abnormal mitochondrial dynamics and neurodegenerative diseases. Biochimica Et Biophysica Acta (BBA)-Molecular Basis of Disease. 2010; 1802:135-142.

**6.** Iwasawa R, Mahul-Mellier A, Datler C, Pazarentzos E, Grimm S. Fis1 and Bap31 bridge the mitochondria–ER interface to establish a platform for apoptosis induction. EMBO J. 2011; 30:556-568.

**7.** Steiner SR, Milton E, Philbert MA. A comparative study of protein carbonylation and mitochondrial dysfunction using the neurotoxicants 1, 3-dinitrobenzene, 3-nitropropionic acid, and 3-chloropropanediol. Neurotoxicology. 2013; 37:74-84.

**8.** Pissadaki EK, Bolam JP. The energy cost of action potential propagation in dopamine neurons: Clues to susceptibility in parkinson's disease. Frontiers in Computational Neuroscience. 2013; 7.

**9.** Detmer SA, Chan DC. Functions and dysfunctions of mitochondrial dynamics. Nature Reviews Molecular Cell Biology. 2007; 8:870-879.

**10.** Abou-Sleiman PM, Muqit MM, Wood NW. Expanding insights of mitochondrial dysfunction in parkinson's disease. Nature Reviews Neuroscience. 2006; 7:207-219.

**11.** O'Donnell KC, Lulla A, Stahl MC, Wheat ND, Bronstein JM, Sagasti A. Axon degeneration and PGC1a-mediated protection in a vertebrate model of a-synuclein toxicity. Disease Models & Mechanisms. 2014.

**12.** Kim J, Moody JP, Edgerly CK, Bordiuk OL, Cormier K, Smith K, Beal MF, Ferrante RJ. Mitochondrial loss, dysfunction and altered dynamics in huntington's disease. Hum Mol Genet. 2010; 19:3919-3935.

**13.** Stewart WF, Schwartz BS, Davatzikos C, Shen D, Liu D, Wu X, Todd AC, Shi W, Bassett S, Youssem D. Past adult lead exposure is linked to neurodegeneration measured by brain MRI. Neurology. 2006; 66:1476-1484.

**14.** Coon S, Stark A, Peterson E, Gloi A, Kortsha G, Pounds J, Chettle D, Gorell J. Whole-body lifetime occupational lead exposure and risk of parkinson's disease. Environ Health Perspect. 2006:1872-1876.

**15.** Weisskopf MG, Weuve J, Nie H, Saint-Hilaire M, Sudarsky L, Simon DK, Hersh B, Schwartz J, Wright RO, Hu H. Association of cumulative lead exposure with parkinson's disease. 2010.

**16.** Gurer-Orhan H, Sabir HU, Özgüneş H. Correlation between clinical indicators of lead poisoning and oxidative stress parameters in controls and lead-exposed workers. Toxicology. 2004; 195:147-154.

**17.** Khan DA, Qayyum S, Saleem S, Khan FA. Lead-induced oxidative stress adversely affects health of the occupational workers. Toxicol Ind Health. 2008; 24:611-618.

**18.** Fan G, Zhou F, Feng C, Wu F, Ye W, Wang C, Lin F, Yan J, Li Y, Chen Y. Lead-induced ER calcium release and inhibitory effects of methionine choline in cultured rat hippocampal neurons. Toxicology in Vitro. 2013; 27:387-395.

**19.** Schaeffer PJ, Wende AR, Magee CJ, Neilson JR, Leone TC, Chen F, Kelly DP. Calcineurin and calcium/calmodulin-dependent protein kinase activate distinct metabolic gene regulatory programs in cardiac muscle. J Biol Chem. 2004; 279:39593-39603.

**20.** Breckenridge DG, Stojanovic M, Marcellus RC, Shore GC. Caspase cleavage product of BAP31 induces mitochondrial fission through endoplasmic reticulum calcium signals, enhancing cytochrome c release to the cytosol. J Cell Biol. 2003; 160:1115-1127.

**21.** Choi SW, Gerencser AA, Nicholls DG. Bioenergetic analysis of isolated cerebrocortical nerve terminals on a microgram scale: Spare respiratory capacity and stochastic mitochondrial failure. J Neurochem. 2009; 109:1179-1191.

**22.** Yadava N, Nicholls DG. Spare respiratory capacity rather than oxidative stress regulates glutamate excitotoxicity after partial respiratory inhibition of mitochondrial complex I with rotenone. J Neurosci. 2007; 27:7310-7317.

**23.** Katsouri L, Parr C, Bogdanovic N, Willem M, Sastre M. PPARy co-activator-1 $\alpha$  (PGC-1 $\alpha$ ) reduces amyloid- $\beta$  generation through a PPARy-dependent mechanism. J Alzheimer's Dis. 2011; 25:151-162.

**24.** O'Donnell KC, Lulla A, Stahl MC, Wheat ND, Bronstein JM, Sagasti A. Axon degeneration and PGC-1alpha-mediated protection in a zebrafish model of alpha-synuclein toxicity. Dis Model Mech. 2014; 7:571-582.

**25.** Spiegelman BM. Transcriptional control of mitochondrial energy metabolism through the PGC1 coactivators. 2007; 287:60.

**26.** St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jäger S, Handschin C, Zheng K, Lin J, Yang W. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell. 2006; 127:397-408.

**27.** Tapia PC. Sublethal mitochondrial stress with an attendant stoichiometric augmentation of reactive oxygen species may precipitate many of the beneficial alterations in cellular physiology produced by caloric restriction, intermittent fasting, exercise and dietary phytonutrients: "Mitohormesis" for health and vitality. Med Hypotheses. 2006; 66:832-843.

**28.** Ciron C, Lengacher S, Dusonchet J, Aebischer P, Schneider BL. Sustained expression of PGC-1alpha in the rat nigrostriatal system selectively impairs dopaminergic function. Hum Mol Genet. 2012; 21:1861-1876.

**29.** Cartoni R, Leger B, Hock MB, Praz M, Crettenand A, Pich S, Ziltener JL, Luthi F, Deriaz O, Zorzano A, Gobelet C, Kralli A, Russell AP. Mitofusins 1/2 and ERRalpha expression are increased in human skeletal muscle after physical exercise. J Physiol. 2005; 567:349-358.

**30.** Martin OJ, Lai L, Soundarapandian MM, Leone TC, Zorzano A, Keller MP, Attie AD, Muoio DM, Kelly DP. A role for peroxisome proliferator-activated receptor gamma coactivator-1 in the control of mitochondrial dynamics during postnatal cardiac growth. Circ Res. 2014; 114:626-636.

**31.** Olanow C, Tatton W. Etiology and pathogenesis of parkinson's disease. Annu Rev Neurosci. 1999; 22:123-144.

**32.** Merrill RA, Dagda RK, Dickey AS, Cribbs JT, Green SH, Usachev YM, Strack S. Mechanism of neuroprotective mitochondrial remodeling by PKA/AKAP1. PLoS Biology. 2011; 9:e1000612.

**33.** Fan M, Rhee J, St-Pierre J, Handschin C, Puigserver P, Lin J, Jäeger S, Erdjument-Bromage H, Tempst P, Spiegelman BM.

Suppression of mitochondrial respiration through recruitment of p160 myb binding protein to PGC-1alpha: modulation by p38 MAPK. Genes Dev. 2004; 1;18(3):278-89.

**34.** Garza A, Vega R, Soto E. Cellular mechanisms of lead neurotoxicity. Med Sci Monit. 2006; 12:RA57-65.

**35.** Kern M, Audesirk G. Stimulatory and inhibitory effects of inorganic lead on calcineurin. Toxicology. 2000; 150:171-178.

**36.** Hernández-Fonseca K, Massieu L. Disruption of endoplasmic reticulum calcium stores is involved in neuronal death induced by glycolysis inhibition in cultured hippocampal neurons. J Neurosci Res. 2005; 82:196-205.

**37.** Chandra D, Choy G, Deng X, Bhatia B, Daniel P, Tang DG. Association of active caspase 8 with the mitochondrial membrane during apoptosis: Potential roles in cleaving BAP31 and caspase 3 and mediating mitochondrion-endoplasmic reticulum cross talk in etoposide-induced cell death. Mol Cell Biol. 2004; 24:6592-6607.

**38.** Breckenridge DG, Stojanovic M, Marcellus RC, Shore GC. Caspase cleavage product of BAP31 induces mitochondrial fission through endoplasmic reticulum calcium signals, enhancing cytochrome c release to the cytosol. J Cell Biol. 2003; 160:1115-1127.

**39.** Gundersen H, Bagger P, Bendtsen T, Evans S, Korbo L, Marcussen N, Møller A, Nielsen K, Nyengaard J, Pakkenberg B. The new stereological tools: Disector, fractionator, nucleator

and point sampled intercepts and their use in pathological research and diagnosis. APMIS. 1988; 96:857-881.

**40.** Nelson JD, Denisenko O, Bomsztyk K. Protocol for the fast chromatin immunoprecipitation (ChIP) method. Nature Protocols. 2006; 1:179-185.